Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
EXEL - Exelixis, Inc.
Market Cap 6.25B P/E 40.85 EPS this Y 14.30% Ern Qtrly Grth -41.60%
Income 153.74M Forward P/E 20.43 EPS next Y 46.90% 50D Avg Chg -
Sales 1.66B PEG 1.12 EPS past 5Y -13.40% 200D Avg Chg 10.00%
Dividend N/A Price/Book 2.44 EPS next 5Y 27.10% 52W High Chg -15.00%
Recommedations 1.90 Quick Ratio 4.75 Shares Outstanding 325.64M 52W Low Chg 29.00%
Insider Own 2.42% ROA 3.17% Shares Float 296.62M Beta 0.68
Inst Own 92.26% ROE 6.34% Shares Shorted/Prior 7.41M/6.77M Price 19.20
Gross Margin 96.45% Profit Margin 9.24% Avg. Volume 2,795,866 Target Price 25.40
Oper. Margin 8.84% Earnings Date Aug 1 Volume 4,554,475 Change -0.78%
Healthcare | Biotechnology | United States
About Exelixis, Inc.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Exelixis, Inc. News
06/08/23 Why Is Exelixis (EXEL) Down 0.6% Since Last Earnings Report?
05/31/23 Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board
05/30/23 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
05/29/23 Exelixis, Inc.'s (NASDAQ:EXEL) market cap decline of US$208m may not have as much of an impact on institutional owners after a year of 4.0% returns
05/29/23 The Smartest Stocks to Buy With $20 Right Now and Hold Forever
05/24/23 2 Under-the-Radar Biotech Stocks to Buy in 2023
05/20/23 2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
05/13/23 Nasdaq Bear Market: 5 Exceptional Growth Stocks You'll Regret Not Buying on the Dip
05/12/23 Exelixis, Inc. (NASDAQ:EXEL) Shares Could Be 49% Below Their Intrinsic Value Estimate
01:52 PM Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y
01:00 AM Exelixis (EXEL) Q1 2023 Earnings Call Transcript
05/09/23 Compared to Estimates, Exelixis (EXEL) Q1 Earnings: A Look at Key Metrics
05/09/23 Exelixis (EXEL) Lags Q1 Earnings and Revenue Estimates
05/09/23 Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
05/08/23 Amid Proxy Challenge From Farallon, Exelixis' Board Member Resigns
05/08/23 Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More
05/07/23 Farallon Capital Management Comments on Successful Campaign for Change at Exelixis
05/07/23 Exelixis, facing challenge from Farallon, says Willsey to exit board
05/07/23 Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
05/03/23 Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
EXEL Chatroom

User Image SweepCast Posted - 8 hours ago

SweepCast ⚡ Unusual Options Detected: $EXEL with Unusual Options Activity Alerted on $20 PUT Expiring: 01-19-2024 worth 125K🐻 |🥇 Start Using SweepCast! @SweepCast 🥇 |

User Image macroaxis Posted - 1 day ago

$EXEL - Next fiscal quarter end is on 30th of June 2023. The standard deviation is down to 1.58... may entail possible volatility slide https://www.macroaxis.com/invest/technicalIndicator/EXEL/Standard-Deviation

User Image Acwild70 Posted - 2 days ago

$EXEL hey Bots. Is this thing ever going to climb?

User Image STCKPRO Posted - 3 days ago

$EXEL NEW ARTICLE : Stifel Nicolaus Remains a Hold on Exelixis (EXEL) https://www.stck.pro/news/EXEL/52358999/

User Image MrStockTimerSaver Posted - 4 days ago

Near or at support: $CRM, $EXEL, $LEN, $DHI

User Image Last10K Posted - 4 days ago

$EXEL just filed with the SEC a Vote of Security Holders https://last10k.com/sec-filings/exel/0000939767-23-000069.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=exel

User Image risenhoover Posted - 4 days ago

Also, if you are new to $EXEL here's a background article on Finpedia for you https://finpedia.co/bin/Exelixis/

User Image risenhoover Posted - 4 days ago

$EXEL / Exelixis files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2023 EXELIXIS, INC. (Exac https://fintel.io/sf/us/exel?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image Quantisnow Posted - 4 days ago

$EXEL 📜 Exelixis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders https://quantisnow.com/i/4603706?utm_source=stocktwits 45 seconds delayed.

User Image fla Posted - 4 days ago

$EXEL [15s. delayed] filed form 8-K on June 05, 16:35:07 https://s.flashalert.me/8RauW

User Image wallstreetscumbag Posted - 5 days ago

$EXEL adding Nov 17th $20 calls for a swing!

User Image ChartMill Posted - 6 days ago

Although the technical rating is only medium, $EXEL does present a nice setup opportunity. https://www.chartmill.com/stock/quote/EXEL/technical-analysis?key=64098b44-e7a8-4645-bf31-97f4d29e12be&utm_source=stocktwits&utm_medium=TA&utm_content=EXEL&utm_campaign=social_tracking

User Image tickeron Posted - 1 week ago

$EXEL enters bullish trend https://srnk.us/go/4699538

User Image Quantisnow Posted - 1 week ago

$EXEL Several insights in the last few minutes: 1. 📜 SEC Form 3 filed by new insider Heyman Tomas J. https://quantisnow.com/i/4598929?utm_source=stocktwits 2. 📜 SEC Form 4 filed by Oliver Bob https://quantisnow.com/i/4598930?utm_source=stocktwits 3. 📜 SEC Form 4 filed by Heyman Tomas J. https://quantisnow.com/i/4598931?utm_source=stocktwits #healthcare

User Image EarningsInsider Posted - 1 week ago

Exelixis, Inc. Files SEC Form 3 $EXEL https://www.marketbeat.com/stocks/NASDAQ/EXEL/sec-filings/

User Image Quantisnow Posted - 1 week ago

$EXEL 📜 SEC Form 3 filed by new insider Oliver Bob https://quantisnow.com/i/4598928?utm_source=stocktwits 45 seconds delayed.

User Image Quantisnow Posted - 1 week ago

$EXEL 📜 SEC Form 4 filed by Smith Julie https://quantisnow.com/i/4598883?utm_source=stocktwits 45 seconds delayed.

User Image Quantisnow Posted - 1 week ago

$EXEL Multiple live insights: 1. 📜 SEC Form SC 13D/A filed by Exelixis Inc. (Amendment) https://quantisnow.com/i/4598029?utm_source=stocktwits 2. 📜 SEC Form 3: New insider Johnson David Edward claimed ownership of 910,730 shares https://quantisnow.com/i/4598040?utm_source=stocktwits 3. 📜 SEC Form 4 filed by Johnson David Edward https://quantisnow.com/i/4598052?utm_source=stocktwits #healthcare

User Image fla Posted - 1 week ago

$EXEL [15s. delayed] filed SEC form 4: Director JOHNSON DAVID EDWARD: Granted 18,176 of Common Stock at price $0 on 2023-05-31, holding 1 https://s.flashalert.me/40Sot1

User Image fla Posted - 1 week ago

$EXEL [15s. delayed] filed SEC form 3: Director JOHNSON DAVID EDWARD: https://s.flashalert.me/XdAI2

User Image fla Posted - 1 week ago

$EXEL [15s. delayed] filed form SC 13D/A on June 02, 17:05:24 https://s.flashalert.me/5XpmUD

User Image Quantisnow Posted - 1 week ago

$EXEL 📜 SEC Form SC 13D/A filed by Exelixis Inc. (Amendment) https://quantisnow.com/i/4597920?utm_source=stocktwits 45 seconds delayed.

User Image fla Posted - 1 week ago

$EXEL [15s. delayed] filed form SC 13D/A on June 02, 16:59:56 https://s.flashalert.me/r0e8Q

User Image tickeron Posted - 1 week ago

How does this affect your portfolio? $EXEL price moved above its 50-day Moving Average. View odds of downtrend. https://srnk.us/go/4694043

User Image svb64 Posted - 05/31/23

$EXEL a new day with new board members? We can hope.

User Image otcdynamics Posted - 05/31/23

$EXEL Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board https://www.otcdynamics.com/exel-farallon-capital-management-comments-on-election-of-all-three-of-its-nominees-to-exelixis-board

User Image STCKPRO Posted - 05/31/23

$EXEL NEW ARTICLE : Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis' Board https://www.stck.pro/news/EXEL/51766540/

User Image Stonkmoon Posted - 05/31/23

$EXEL 2023-05-31 12:30 ET Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board https://stonkmoon.com/news/EXEL/56f888e5b271744c4d35497bd91a7eb1

User Image Quantisnow Posted - 05/31/23

$EXEL 📰 Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis' Board https://quantisnow.com/i/4582852?utm_source=stocktwits 45 seconds delayed.

User Image WebChronicleToday Posted - 05/31/23

$EXEL New Press Release: Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board Farallon Capital Management, L.L.C. (“Farallon”) manages funds that own approximately 7.8% of the outstanding shares of Exelixis, Inc. (NASDAQ: EXEL) (“Exelixis” or the “Company”), making it the Company’s largest active shareholder. Farallon today commented on the preliminary results of Exelixis’ 2023 Annual Meeting of Shareholders (the “Annual Meeting”), including the election to the Board of Directors (the “Board”) of all three Farallon director candidates: Tom Heyman, Dave Johnson and Bob Oliver. Farallon stated: “We are pleased that our three exceptional nominees were elected to the Board of Exelixis and would like to thank our fellow shareholders for their engagement and overwhelming su (...) https://webchronicletoday.com?p=364356

Analyst Ratings
JMP Securities Market Outperform May 10, 23
EF Hutton Buy Apr 28, 23
Morgan Stanley Equal-Weight Apr 12, 23
EF Hutton Buy Mar 20, 23
Wells Fargo Overweight Mar 9, 23
EF Hutton Buy Mar 3, 23
EF Hutton Buy Feb 14, 23
Piper Sandler Overweight Feb 8, 23
EF Hutton Buy Feb 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Apr 03 Sell 20.01 38,930 778,989 582,435 04/05/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Apr 03 Option 14.74 13,930 205,328 621,365 04/05/23
WYSZOMIERSKI JACK L Director Director Mar 10 Sell 16.61 15,300 254,133 317,467 03/14/23
WYSZOMIERSKI JACK L Director Director Mar 10 Option 6.3 40,000 252,000 332,767 03/14/23
Garber Alan M Director Director Feb 21 Sell 17.49 40,000 699,600 31,417 02/23/23
Garber Alan M Director Director Feb 21 Option 6.3 40,000 252,000 71,417 02/23/23
FELDBAUM CARL B Director Director Feb 09 Sell 17.78 40,000 711,200 18,701 02/10/23
FELDBAUM CARL B Director Director Feb 09 Option 6.3 40,000 252,000 58,701 02/10/23
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 06 Sell 17.37 25,000 434,250 254,414 02/08/23
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 06 Option 4.2 25,000 105,000 279,414 02/08/23
MORRISSEY MICHAEL President and CEO President and CEO Jan 24 Option 4.2 100,000 420,000 440,655 01/26/23
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Sell 15.88 20,000 317,600 410,958 12/16/22
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Option 4.2 20,000 84,000 430,958 12/16/22
POSTE GEORGE Director Director Nov 29 Option 6.3 40,000 252,000 233,189 12/01/22
POSTE GEORGE Director Director Nov 29 Sell 16.68 40,000 667,200 193,189 12/01/22
Haley Patrick J. EVP, Commercial EVP, Commercial Sep 12 Option 6.21 40,000 248,400 301,591 09/14/22
Haley Patrick J. EVP, Commercial EVP, Commercial Sep 12 Sell 17.94 40,000 717,600 261,591 09/14/22
Senner Christopher J. EVP and CFO EVP and CFO Aug 11 Option 6.21 225,000 1,397,250 670,882 08/12/22
Haley Patrick J. EVP, Commercial EVP, Commercial May 27 Sell 18.21 18,812 342,567 239,818 06/01/22
WILLSEY LANCE Director Director May 12 Option 3.13 40,000 125,200 464,415 05/13/22
WILLSEY LANCE Director Director May 12 Sell 19.65 40,000 786,000 424,415 05/13/22
WYSZOMIERSKI JACK L Director Director Apr 04 Option 3.13 40,000 125,200 279,888 04/06/22
WYSZOMIERSKI JACK L Director Director Apr 04 Sell 23 6,696 154,008 273,192 04/06/22
Haley Patrick J. EVP, Commercial EVP, Commercial Mar 31 Option 6.21 20,000 124,200 279,191 04/04/22
Haley Patrick J. EVP, Commercial EVP, Commercial Mar 31 Sell 22.72 20,000 454,400 269,191 04/04/22
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Mar 28 Sell 22 18,000 396,000 605,236 03/30/22
Garber Alan M Director Director Mar 01 Option 3.13 40,000 125,200 52,718 03/03/22
Garber Alan M Director Director Mar 01 Sell 21 21,301 447,321 31,417 03/03/22
Hessekiel Jeffrey EVP and General Coun.. EVP and General Counsel Feb 24 Sell 20 18,000 360,000 555,361 02/28/22
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 25 Sell 19.53 31,238 610,078 198,476 02/28/22
PAPADOPOULOS STELIOS Director Director Feb 22 Sell 19.56 84,515 1,653,113 1,220,036 02/24/22
FELDBAUM CARL B Director Director Feb 22 Option 3.13 20,000 62,600 28,521 02/24/22
FELDBAUM CARL B Director Director Feb 22 Sell 19.49 20,000 389,800 8,521 02/24/22
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 03 Option 1.9 60,000 114,000 305,241 02/04/22
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 03 Sell 17.91 60,000 1,074,600 245,241 02/04/22
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Option 6.21 47,500 294,975 410,672 12/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Sell 17.44 47,500 828,400 363,172 12/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Oct 15 Sell 21.92 47,500 1,041,200 411,240 10/15/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Oct 15 Option 6.21 47,500 294,975 458,740 10/15/21
Haley Patrick J. EVP, Commercial EVP, Commercial Sep 17 Sell 20.36 25,000 509,000 280,994 09/17/21
Haley Patrick J. EVP, Commercial EVP, Commercial Sep 17 Option 1.7 25,000 42,500 305,994 09/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Sep 17 Sell 20.46 47,500 971,850 389,467 09/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Sep 17 Option 6.21 47,500 294,975 436,967 09/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Aug 18 Sell 18.44 55,000 1,014,200 389,467 08/18/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Aug 18 Option 1.9 55,000 104,500 444,467 08/18/21
COHEN CHARLES Director Director Jul 08 Option 4.72 80,000 377,600 261,375 07/08/21
Haley Patrick J. EVP, Commercial EVP, Commercial May 18 Sell 24.73 14,593 360,885 280,994 05/18/21
MARCHESI VINCENT T Director Director May 17 Option 6.3 40,000 252,000 106,115 05/17/21
MORRISSEY MICHAEL President and CEO President and CEO May 14 Option 4.2 50,000 210,000 541,813 05/14/21
Schwab Gisela Pres, Prod Dev & Med.. Pres, Prod Dev & Med Aff & CMO May 14 Option 1.9 100,000 190,000 714,078 05/14/21